Shanghai Yuanqi Biopharma, a subsidiary of Rui'ang Gene, has been granted a
national invention patent for a 15‑color full‑spectrum flow cytometry reagent
kit and monitoring method to detect minimal residual disease (MRD) in acute
B‑cell lymphoblastic leukemia.